MedTrace Logo

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

NCT00891930 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2024-07-17

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate the mechanism(s) of resistance to the anti-epidermal growth factor receptor (EGFR) antibody panitumumab given in combination with irinotecan in metastatic colorectal carcinoma (mCRC) patients with wild-type Kirsten rat sarcoma-2 virus oncogene (KRAS) tumor status at the time of initial diagnosis.

Conditions

Interventions

BIOLOGICAL

Panitumumab

Panitumumab 6 mg/kg administered via IV infusion over 60 minutes

BIOLOGICAL

Ganitumab

AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes

DRUG

Irinotecan

Irinotecan starting dose of 180 mg/m² adminstered via IV infusion

Sponsors & Collaborators

  • NantBioScience, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-05
Primary Completion
2013-07-22
Completion
2013-07-22

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00891930 on ClinicalTrials.gov